LianBio halts infigratinib CCA program after Helsinn exits US market

LianBio

Helsinn Healthcare SA permanently discontinues Truseltiq (infigratinib) in US; plans to withdraw NDA for business reasons.
BridgeBio closing global Phase 3 PROOF-301 trial of infigratinib in first-line cholangiocarcinoma (CCA).
LianBio terminating all CCA development in China; no longer pursuing infigratinib for CCA in licensed territories.
LianBio will continue supporting existing patients under the Hainan Named Patient Program.
LianBio expects to continue Phase 2a trial of infigratinib in gastric cancer and other FGFR-altered solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.